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Aims: Lipid soluble vitamin E plays a role in several physiological mechanisms, however, the mechanism of this
action is controversial. We investigated how tocopherol (α-tocopherol acid succinate) inﬂuences the eﬀects of
cyclooxygenase inhibitors (COXi) in the smooth muscles.
Main methods: The contractility of the samples from 22-day-pregnant myometrium and non-pregnant myome-
trium and trachea was determined in an isolated organ bath in vitro. The activity of cyclooxygenase enzymes
(COX) was also measured in the tissues.
Key ﬁndings: Diclofenac (10−9–10−5 M) and rofecoxib (10−10–10−5 M) decreased the contractions in non-
pregnant and 22-day-pregnant uteri. Tocopherol (10−7 M) increased the relaxant eﬀect only in pregnant uteri.
Both diclofenac (10−9–10−5 M) and rofecoxib (10−10–10−5 M) reduced the tracheal tones, while they were
slightly intensiﬁed by pretreatment with tocopherol (10−7 M). Tocopherol enhanced the contractions of preg-
nant uteri. Tocopherol (10−7 M) itself can induce the cyclooxygenase activity and shift the COX-1 and COX-2
ratio to COX-2. The lowest COX activity was found in non-pregnant uteri, while the highest one was in the
trachea.
Signiﬁcance: The COX enzymes, especially COX-2, play an important role in the contraction of pregnant uteri in
rat. Tocopherol has a tissue speciﬁc COX-2 activity increasing eﬀect in pregnant rat uterus but has no such action
in non-pregnant uteri or tracheal tissue. Hereby, tocopherol may intensify selectively the uterine relaxing eﬀect
of COX-2 inhibitors in preterm contractions. However, tocopherol can enhance the contractile response of
pregnant uterus that may increase the risk of premature contractions.
1. Introduction
Vitamin E is a lipid-soluble compound with high peroxyl radical
scavenger ability. Vitamin E includes eight natural analogs, such as α-,
β-, γ-, and δ-tocopherols and α-, β-, γ-, and δ-tocotrienols, however,
their activity is quite various [1]. α-tocopherol is the most frequently
used analog. Over the past thirty years, many studies have been pub-
lished on the biological eﬀects and functions of vitamin E, e.g. it is
needed for reproduction [2] and may help to prevent Alzheimer's dis-
ease, non-alcoholic fatty liver diseases (NAFLD and NASH) of non-
diabetic patients, atherosclerosis and certain types of cancer [3–7]. The
mechanism of action of vitamin E has not yet been fully clariﬁed. It can
get across the cell membrane and can bind to many intracellular re-
ceptors and enzymes and may lead to modifying their functions [8]. For
example, tocopherols can increase the activity of estrogen receptor β
(ERβ) [9], inhibit activities of protein kinase C alpha [10], phospholi-
pase A2 [11] and protein tyrosine kinases [12]. Moreover, vitamin E
can also inﬂuence the action of other drugs by its antioxidant eﬀect that
shows tissue speciﬁcity. The tracheal tone-reducing eﬀect of β2-agonist
terbutaline was decreased in female estrous rat by pretreatment with α-
tocopherol, while in pregnant uterus the pretreatment was ineﬃcient.
This diﬀerence was explained by the various oxidative states of smooth
muscles [13].
The interaction between tocopherols and cyclooxygenase enzymes
(COX) was investigated in a few studies. Wu et al. [14] reported vitamin
E inhibited the activity of cyclooxygenase enzymes in human aortic
endothelial cells. Moreover, vitamin E can aﬀect the diﬀerent steps of
the arachidonic acid cascade, but this eﬀect may be diverse in tissues.
According to literature, prostaglandin E2 (PGE2) production was re-
duced in mouse [15,16] and rat [17] macrophages by vitamin E.
Analogs of tocopherols have diﬀerent eﬀects on COX. Alpha-tocopherol
succinate inhibited more eﬃciently the LPS-stimulated PGE2 produc-
tion in macrophages and the COX activity in human lung epithelial cells
than the other analogs [18,19].
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) inhibit COX-1 or
COX-2 enzymes, hereby decrease the liberation of prostaglandins (PG).
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The low level of PGE2 induces the relaxation of the uterine smooth
muscle, although the clinical use of NSAIDs for the prevention of pre-
term birth is limited because of the side eﬀects [20]. Non-COX selective
NSAIDs, especially acetyl-salicylic acid, are responsible for aspirin-in-
duced asthma (AIA), while COX-2 selective compounds seem to be
helpful not to exacerbate asthmatic symptoms [21].
We hypothesize that tocopherols modiﬁes the COX activity and the
eﬀect of NSAIDs that may have signiﬁcance in smooth muscle con-
tractions. Accordingly, the aim of this study is to investigate how α-
tocopherol acid succinate (tocopherol) inﬂuences the eﬀects of non-
selective and selective COX inhibitors (COXi) in the non-pregnant and
pregnant uterine, and tracheal smooth muscle contractions in rats in
vitro.
2. Materials and methods
All experiments involving animal subjects were carried out with the
approval of the Hungarian Ethical Committee for Animal Research
(permission number: IV/198/2013). The animals were treated in ac-
cordance with the European Communities Council Directives (86/609/
ECC) and the Hungarian Act for the Protection of Animals in Research
(Article 32 of Act XXVIII).
2.1. Housing and handling of the animals
Sprague-Dawley rats were procured from INNOVO Ltd. (Gödöllő,
Hungary) and were kept at a controlled temperature (22 ± 3 °C), with
30–70% relative humidity, on a 12 h dark-light cycle. The animals were
fed with standard rodent pellet diet (Charles-River Laboratories,
Budapest, Hungary) and given tap water ad libitum.
2.2. Mating of the animals
The mature female Sprague-Dawley rats (180–200 g) were selected
by the estrus cycle. The estrus cycle was measured by the vaginal im-
pedance of rats with an Estrus Cycle Monitor EC40 (Fine Science Tools.
Foster City, CA, USA). The female in estrus and sexually mature male
(240–260 g) rats were placed into a special mating cage with two
rooms. There was a time-controlled movable metal door between the
rooms. The separating door was pulled up before dawn.
In the morning, vaginal smears were taken from the female rats.
Successful copulation was indicated by the presence of sperm in the
native vaginal smear or a copulation plug. This day meant the ﬁrst day
of pregnancy.
2.3. Isolated organ bath studies
2.3.1. Preparation of uteri
The animals were terminated by CO2 inhalation. Two horns of uteri
were excised, 5-mm-long muscle rings were sliced and mounted verti-
cally in an organ bath containing 10 ml of de Joung solution (compo-
sition in Mm: 137 NaCl, 3 KCl, 1 CaCl2, 1 MgCl2, 12 NaHCO3, 4
NaH2PO4, 6 glucose, pH 7.4). The organ bath was heated at 37 °C and
carbogen (95% O2 + 5% CO2) was bubbled into the chambers. After
the setting of initial tension (1.5 g), myometrial rings were incubated
with a buﬀer change every 15 min for about 1 h. Tocopherol was dis-
solved in mixture of ethanol 96%: Macrogol 400 (1:14) and diluted
further in Macrogol 400. The control tissues have been treated with the
solvent without tocopherol and results with tocopherol have been
corrected with these values. The samples were equilibrated for another
60 min with tocopherol (10−7 M). Tocopherol was added to tissues
after every wash of buﬀer solution. The control preparations were in-
cubated for 1 h without tocopherol. Cumulative dose-response curves of
non-selective COXi diclofenac (10−9–10−5 M) and COX-2 selective
inhibitor rofecoxib (10−10–10−5 M) were obtained.
2.3.2. Preparation of trachea
Trachea tissues were dissected from non-pregnant estrous rats
(160–260 g, n = 8), then the esophagus and blood vessels were re-
moved. The tracheal tube was cut transversally into 4–5- mm-wide
rings, which were placed in Krebs buﬀer (composition in mM: 118
NaCl; 4.75 KCl; 2.5 CaCl2; 1.19 K2HPO4; 25 NaHCO3; 1.2 MgSO4 and 11
glucose). The tracheal rings were mounted with their longitudinal axis
vertically by hooks. The initial strain was set to about 2.00 g. The
samples were equilibrated for 1 h, while the buﬀer solution was
changed in every 15 min. After that, the tissues were incubated for
another 60 min with tocopherol (10−7 M) with further buﬀer change in
every 15 min. Except for the control preparations, tocopherol was ap-
plied after every wash of buﬀer solution. Cumulative dose-response
curves of non-selective COXi diclofenac (10−9–10−5 M) and COX-2
selective inhibitor rofecoxib (10−10–10−5 M) were obtained.
2.3.3. Measurement of COX enzymes activity
The smooth muscle samples (22-day-pregnant and non-pregnant
myometrium, trachea, n = 6/group) were incubated in an organ bath
as described above. After the incubated period, tissues were perfused
with cold Tris Buﬀer pH 7.4 to remove any red blood cells and clots,
frozen in liquid nitrogen and stored at −80 °C until assay. On the day
of measurement, samples were homogenized in 5 ml of cold buﬀer
(0.1 M Tris-HCl, pH 7.8, containing 1 mM EDTA) per gram tissue,
centrifuged at 10,000 ×g for 15 min at 4 °C. The supernatant was
stored on ice. The activity of COX enzymes was determined by COX
Activity Assay Kit (Cayman chemicals, Ann Arbor, MI). This Kit mea-
sures the peroxidase activity of COX. The peroxidase activity is assayed
with the colorimetric method by monitoring the appearance of oxidized
N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD) at 590 nm.
2.4. Statistical analysis
All data were analyzed by the Prism 5.01 (GraphPad Software, USA)
computer program. The values were statistically evaluated with the
unpaired t-test or ANOVA with Tukey Multiple Comparison Test.
3. Results
3.1. Isolated organ bath studies
Pretreatment with tocopherol signiﬁcantly enhanced the contrac-
tions of the 22-day-pregnant myometrium (Fig. 1 striped columns) but
did not alter it in non-pregnant uteri (Fig. 1 empty columns).
The non-selective COX inhibitor diclofenac (10−9–10−5 M) and the
selective COX-2 inhibitor rofecoxib (10−10–10−5 M) inhibited the
contractions of non-pregnant uteri in a concentration-dependent
manner. In the presence of tocopherol, the relaxant eﬀects of diclofenac
and rofecoxib did not change (Fig. 2).
In 22-day-pregnant smooth muscle uteri the relaxant eﬀect of se-
lective COX-2 inhibitor rofecoxib was higher than that of diclofenac.
After pretreatment with tocopherol, the relaxant eﬀect was increased
signiﬁcantly in each concentration in the case of both compounds
(Fig. 3).
Both diclofenac (10−9–10−5 M) and rofecoxib (10−10–10−5 M)
also reduced the tone of tracheal tissues. The average tone decrease by
diclofenac and rofecoxib was 46.8 ± 5.0 mg and 32.6 ± 10.4 mg,
respectively. Tocopherol inﬂuenced the eﬀect of diclofenac and rofe-
coxib only in lower concentrations (Fig. 4).
When one dose of selective COX-2 inhibitor rofecoxib (10−7 M) was
applied before KCl-evoked control contractions on 22-day pregnant
uteri, the activity of diclofenac stayed low, while in the presence of
tocopherol it augmented slightly (Fig. 5A).
Besides, if we added one dose of selective COX-1 inhibitor SC-560
before eliciting control contraction, the relaxing eﬀect of rofecoxib was
enhanced and the presence of tocopherol kept on increasing this eﬀect
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(Fig. 5B).
3.2. Measurement of COX enzymes activity
The highest level of total COX activity was found in trachea tissues,
while the lowest was in non-pregnant uteri. After pretreatment with
tocopherol, neither the COX activity of the trachea nor the COX activity
of non-pregnant uteri changed. In 22-day-pregnant myometrium the
total cyclooxygenase enzymes activity was signiﬁcantly increased by
pretreatment with tocopherol. The activity of COX-1 enzyme was not
altered in the tissues in the presence of tocopherol. However, the ac-
tivity of COX-2 enzyme was enhanced signiﬁcantly in tocopherol pre-
treated 22-day-pregnant uteri (Fig. 6).
4. Discussion
In this study, we have demonstrated that α-tocopherol succinate
modiﬁes the relaxant eﬀect of NSAID's via the increase of the activity of
COX-2 in 22-day-pregnant rat uteri. These ﬁndings may open up a new
therapeutic use for tocopherols. On the other hand, the use of toco-
pherol during pregnancy may intensify the premature contractions.
The levels of PGE2, PGF2α, COX enzymes and other proteins and
enzymes which play a role in reproduction, pregnancy and parturition
are rather various in non-pregnant and pregnant uteri [22–24]. More-
over, in the last weeks of human pregnancy, diﬀerent biological me-
chanisms are developed to prepare uteri for labor. Gap junctions and
ion channels protein are activated in phase 1 of labor, while myometrial
contractions are enhanced by oxytocin and prostaglandins in phase 2
[25].
Cyclooxygenase enzymes (COX-1, COX-2) catalyze the transforma-
tion of arachidonic acid to prostaglandins. It is generally accepted that
PGs play an important role in parturition by inducing myometrial
contraction and relaxation via EP1, EP3 and EP2, EP4 receptors [26].
On the other hand, there is no general agreement in literature as to
which isoenzyme of cyclooxygenase leads to the liberation of pros-
taglandins at the time of parturition.
St-Louis et al. [27] described that the expression of COX-1 enzyme
was elevated at time of parturition, while the presence of COX-2 was less
in pregnant rat endometrium. In the case of non-pregnant rat en-
dometrium, the amounts of both COX-1 and COX-2 enzymes were equal
in the estrous phase. In other studies, the expression of COX-2 was en-
hanced in rodent myometrium during parturition, hence COX-2 derived
PGs were determinant in the ﬁnal pathway of parturition [28]. Fur-
thermore, the increased expression of COX-2 led to a high level of PGE2,
since the expression of COX-1 remained low and was not altered with
gestational age in human uteri [29]. In our experiment, in non-pregnant
uteri the activity of the COX-1 and COX-2 ratio was about equal, while in
pregnant uteri the activity of COX-2 was moderately lower than that of
COX-1 enzyme. In addition, the total COX activity of pregnant uteri was
higher than in non-pregnant samples. The maximum eﬀect of selective
COX-2 inhibitor rofecoxib was more powerful than that of non-selective
diclofenac both in pregnant and non-pregnant uteri. However, diclofenac
as non-selective COX inhibitor is 20-fold more potent for COX-2 than
COX-1 [30,31]. These results suggest that both COX-1 and COX-2 en-
zymes play a role in uterine contractions, nevertheless, the relaxation
mostly depends on COX-2 inhibition. The relaxant eﬀect of diclofenac
and rofecoxib was stronger in non-pregnant than in pregnant uteri,
which can be explained by the activities of COX-1 and COX-2 in these
n
p
-u
te
ru
s
 c
o
n
tr
o
l
n
p
-u
te
ru
s
 t
o
c
o
p
h
e
ro
l
p
-u
te
r
u
s
 c
o
n
tr
o
l
p
-u
te
r
u
s
 t
o
c
o
p
h
e
r
o
l
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
***
ns
AU
C
Fig. 1. The area under the curve of KCl-evoked uterus contractions after the incubation
with tocopherol. The presence of tocopherol did not alter the contraction of non-pregnant
myometrium (empty columns), but increased it signiﬁcantly in 22-day-pregnant uteri
(striped columns). The statistical analyses were carried out with the two-tailed unpaired t-
test. (ns: not-signiﬁcant; *** p < 0.001). Each value denotes the mean ± S.E.M, n = 6.
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Fig. 2. Eﬀect of non-selective COXi diclofenac (A) and selective COX-2 inhibitor rofecoxib
(B) on KCl-evoked control contraction of non-pregnant rat uteri alone and in the presence
of tocopherol (10−7 M). Tocopherol changed the eﬀect of neither diclofenac nor rofe-
coxib. The statistical analyses were carried out with the two-tailed unpaired t-test. Each
value denotes the mean ± S.E.M, n = 6.
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tissues. In non-pregnant uteri, the COX1/COX2 ratio is 1.09, which
means that the two isoenzymes have similar activity. However, in
pregnant uteri the COX-1 activity was 1.22, showing the greater activity
of COX-1. This is further evidence that the amount of COX-2 determines
the relaxing eﬃcacy of COXi: less COX-2 means less eﬃcacy, while more
COX-2 means higher eﬃcacy in the relaxing eﬀect of COXi.
Several studies have shown the relationship between tocopherol and
cyclooxygenase enzymes. Abate et al. [32] demonstrated that vitamin E
reduced LPS-mediated COX-2 induction alone and in combination with
aspirin in macrophages. Moreover, O'Leary et al. [33] reported that
tocopherols decreased the activity of COX-2 in Caco2 cells. The lim-
itation of these reports is that the investigations were done in cultured
cells. Additionally, only few papers have focused on the connection of
tocopherol and cyclooxygenase enzymes in uteri. According to our re-
sults, pretreatment with tocopherol unambiguously raised the area
under the curve of KCl-evoked contractions in pregnant uteri. This
implies that tocopherol may enhance the contractibility of pregnant
myometrium. Interestingly, the inﬂuence of tocopherol was not de-
tectable in the case of non-selective COX inhibitor diclofenac either in
non-pregnant or in 22-day pregnant uteri. These results suggest that, in
contrast to earlier ﬁndings, pretreatment with tocopherol may increase
the contractility of uteri by enhancing the activity of COX-2 enzyme,
and hereby the relaxant eﬀect of COX inhibitors may be more pro-
nounced, especially in the case of selective COX-2 inhibitors. To con-
ﬁrm this hypothesis, the alteration of the activity of COX enzymes was
measured in the tissues before and after the incubation with tocopherol.
Tocopherol itself induced the COX activity and shifted the COX-1 and
COX-2 ratio to COX-2 in pregnant uteri. When COX-1 enzymes were
blocked by selective inhibitor SC-560, the relaxant eﬀect of rofecoxib
increased alone and further increased in the presence of tocopherol.
However, when COX-2 was inhibited by the selective blocker rofecoxib,
the dose-response curve of diclofenac was shifted slightly left, and after
pretreatment with tocopherol the signiﬁcant diﬀerence between the
curves practically ceased. These ﬁndings provide further evidence that
COX-2 is predominant in pregnant uterine contraction and the toco-
pherol-induced modiﬁcation of the COX-1 and COX-2 ratio led to the
increased relaxing eﬃcacy of COX inhibitors.
In trachea tissues the levels of COX-1 and COX-2 activity were equal
(the COX-1/COX-2 ratio was 0.97), which correlates with the previous
ﬁndings in literature [34,35]. Diclofenac decreased the tracheal tone
more than rofecoxib, suggesting that COX-1 derived prostaglandins
may play a larger role in airway smooth muscle contraction in rat. In-
terestingly, pretreatment with tocopherol increased the relaxing eﬀects
of rofecoxib and diclofenac, but only in low concentrations of the drugs.
We have no clear explanation for this phenomenon, but it might be
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Fig. 3. Eﬀect of non-selective COXi diclofenac (A) and selective COX-2 inhibitor rofecoxib
(B) on KCl-evoked control contraction of 22-day-pregnant rat uteri with or without to-
copherol (10−7 M). After pretreatment with tocopherol, the relaxation eﬀect of diclo-
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mean ± S.E.M, n = 6. (*p < 0.05; **p < 0.01; ***p < 0.001).
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Fig. 4. Tone-reducing eﬀect of non-selective COXi diclofenac (A) and selective COX-2
inhibitor rofecoxib (B) on estrous rat trachea tissues. In the presence of tocopherol the
eﬀect of both compounds was signiﬁcantly increased only in low concentrations. The
statistical analyses were carried out with the two-tailed unpaired t-test. Each value de-
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A. Kothencz et al. Life Sciences 192 (2018) 199–204
202
related to the weak antioxidant capacity of rat trachea as compared
with pregnant uterus [13].
5. Conclusions
Pretreatment with tocopherol can strengthen COX-2 activity in
pregnant uteri, leading to the stronger relaxant eﬀect of COX-2 in-
hibitor. Our results suggest that COX enzymes, especially COX-2, play
an important role in the contraction of pregnant uteri in rat. Tocopherol
has a tissue speciﬁc COX-2 activity increasing eﬀect in pregnant rat
uterus but has no such action in non-pregnant uteri or tracheal tissue.
Hereby tocopherol may intensify selectively the uterine relaxing eﬀect
of COX-2 inhibitors in preterm contractions. However, tocopherol alone
can enhance the contractile response of pregnant uterus that may in-
crease the risk of premature contractions. The use of vitamin prepara-
tions containing Vitamin E derivatives may modify the contractility of
the pregnant uterus and its pharmacological response to contractile
agents and COX-inhibitors. Our results raise the necessity of studies for
further preclinical and clinical clariﬁcation of the correlation between
tocopherol level and pregnant uterine contraction.
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Fig. 5. The relaxant eﬀect of non-selective COXi diclofenac after pretreatment with se-
lective COX-2 inhibitor rofecoxib (10−7 M) (A) and the concentration-response curve of
selective COX-2 inhibitor rofecoxib after pretreatment with selective COX-1 inhibitor SC-
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% ± S.E.M. The statistical analyses were carried out with the two-tailed unpaired t-test.
(ns: not signiﬁcant; *p < 0.05; **p < 0.01; ***p < 0.001).
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Fig. 6. The eﬀect of tocopherol on the activity of COX-enzymes in non-pregnant uterus (np)
(empty columns), 22-day-pregnant uterus (p) (striped columns) and estrous trachea (ﬁlled
columns). The pretreatment with tocopherol increased the activity of total COX- enzymes
only in pregnant uterus (A). In the case of COX-1 activity, no signiﬁcant alteration was
determined (B). The activity of COX-2 was enhanced by the presence of tocopherol in
pregnant animals (C). The statistical analyses were carried out with ANOVA Tukey test. (ns:
not signiﬁcant; ***p < 0.001) Each value denotes the mean ± S.E.M., n = 6.
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